CorMedixCRMD
CRMD
About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Employees: 82
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
5% more funds holding
Funds holding: 129 [Q4 2024] → 135 (+6) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
1.8% less ownership
Funds ownership: 37.83% [Q4 2024] → 36.03% (-1.8%) [Q1 2025]
19% less call options, than puts
Call options by funds: $4.77M | Put options by funds: $5.89M
22% less capital invested
Capital invested by funds: $186M [Q4 2024] → $145M (-$41.3M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
18%
downside
Avg. target
$14
4%
downside
High target
$15
3%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger | 3%upside $15 | Buy Maintained | 7 May 2025 |
D. Boral Capital Jason Kolbert | 3%upside $15 | Buy Maintained | 6 May 2025 |
RBC Capital Gregory Renza | 18%downside $12 | Outperform Reiterated | 26 Mar 2025 |
Financial journalist opinion
Based on 4 articles about CRMD published over the past 30 days
Positive
Seeking Alpha
1 week ago
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis market.
Positive
Seeking Alpha
1 week ago
CorMedix: Exceeding Expectations
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth.
Neutral
GlobeNewsWire
2 weeks ago
CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference
BERKELEY HEIGHTS, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the Jefferies Global Healthcare Conference, taking place in New York on June 3 - 5, 2025.
Neutral
Investors Business Daily
3 weeks ago
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
GlobeNewsWire
1 month ago
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC Capital Markets Global Healthcare Conference, taking place in New York on May 20-21, 2025.
Positive
Zacks Investment Research
1 month ago
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neutral
Seeking Alpha
1 month ago
CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript
CorMedix, Inc. (NASDAQ:CRMD ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executive Vice President and Chief Financial Officer Liz Hurlburt – Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Gregory Renza – RBC Capital Roana Ruiz – Leerink Partners Leszek Sulewski – Truist Securities Serge Belanger – Needham & Company Operator Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode.
Positive
Zacks Investment Research
1 month ago
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to loss of $0.25 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ.
Neutral
GlobeNewsWire
1 month ago
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
Charts implemented using Lightweight Charts™